UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2016
NovoCure Limited
(Exact name of registrant as specified in its charter)
Jersey |
001-37565 |
98-1057807 |
(State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(IRS Employer Identification No.) |
Le Masurier House
La Rue Le Masurier
St. Helier, Jersey JE2 4YE
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: +44 (0)15 3475 6700
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. to Form 8-K):
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On September 7, 2016, William Doyle, the executive chairman of NovoCure Limited (the “Company”), will provide a business update at the Wells Fargo 2016 Healthcare Conference, scheduled for 2:55 pm Eastern. Mr. Doyle will announce that more than 900 active patients are on treatment with Optune. The audio replay and presentation materials will be available via the Company’s website for at least 14 days following the presentation.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited
(Registrant)
Date: September 7, 2016
|
|
|
By: |
|
/s/ Wilhelmus Groenhuysen |
|
|
Name: Wilhelmus Groenhuysen |
|
|
Title: Chief Financial Officer |